Cigna Group (NYSE:CI) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen downgraded shares of Cigna Group (NYSE:CI) from a buy rating to a hold rating in a research report sent to investors on Saturday morning.

Several other equities research analysts have also recently commented on the company. Wolfe Research reissued an “outperform” rating and issued a $315.00 target price on shares of Cigna Group in a research note on Tuesday, June 16th. Wells Fargo & Company upped their price target on Cigna Group from $305.00 to $307.00 and gave the company an “equal weight” rating in a research note on Friday. Piper Sandler decreased their price target on Cigna Group from $370.00 to $346.00 and set an “overweight” rating on the stock in a report on Wednesday, June 3rd. UBS Group lifted their price objective on Cigna Group from $375.00 to $400.00 and gave the stock a “buy” rating in a research report on Friday, May 22nd. Finally, The Goldman Sachs Group boosted their price objective on Cigna Group from $335.00 to $340.00 and gave the stock a “buy” rating in a report on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Cigna Group presently has a consensus rating of “Moderate Buy” and an average price target of $341.60.

Cigna Group Price Performance

Shares of CI stock opened at $279.27 on Friday. Cigna Group has a 1 year low of $239.51 and a 1 year high of $315.47. The company has a current ratio of 0.76, a quick ratio of 0.73 and a debt-to-equity ratio of 0.68. The firm’s 50 day moving average is $286.62 and its 200-day moving average is $281.10. The firm has a market capitalization of $73.88 billion, a price-to-earnings ratio of 11.55, a PEG ratio of 1.08 and a beta of 0.29.

Cigna Group (NYSE:CI) last issued its quarterly earnings results on Thursday, July 30th. The health services provider reported $7.78 earnings per share for the quarter, beating analysts’ consensus estimates of $7.60 by $0.18. Cigna Group had a net margin of 2.27% and a return on equity of 19.75%. The business had revenue of $70.04 billion during the quarter, compared to analyst estimates of $70.14 billion. During the same quarter last year, the business posted $7.20 earnings per share. Cigna Group’s revenue for the quarter was up 6.7% compared to the same quarter last year. Cigna Group has set its FY 2026 guidance at 30.450- EPS. Sell-side analysts forecast that Cigna Group will post 30.5 EPS for the current fiscal year.

Cigna Group Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be paid a $1.56 dividend. The ex-dividend date of this dividend is Tuesday, September 8th. This represents a $6.24 dividend on an annualized basis and a dividend yield of 2.2%. Cigna Group’s dividend payout ratio is 26.45%.

Insider Buying and Selling at Cigna Group

In other Cigna Group news, CAO Jamie G. Kates sold 899 shares of the stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $298.61, for a total value of $268,450.39. Following the transaction, the chief accounting officer owned 2,368 shares of the company’s stock, valued at approximately $707,108.48. This represents a 27.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO David Cordani sold 201,878 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $292.82, for a total value of $59,113,915.96. Following the transaction, the chief executive officer owned 34,337 shares in the company, valued at approximately $10,054,560.34. This trade represents a 85.46% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.60% of the stock is owned by company insiders.

Institutional Trading of Cigna Group

Institutional investors and hedge funds have recently modified their holdings of the stock. Evercore Wealth Management LLC boosted its stake in Cigna Group by 2.8% during the 1st quarter. Evercore Wealth Management LLC now owns 1,301 shares of the health services provider’s stock worth $347,000 after acquiring an additional 35 shares during the last quarter. Cary Street Partners Investment Advisory LLC increased its stake in Cigna Group by 11.0% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 363 shares of the health services provider’s stock valued at $100,000 after purchasing an additional 36 shares in the last quarter. OLD National Bancorp IN increased its stake in Cigna Group by 3.7% in the fourth quarter. OLD National Bancorp IN now owns 1,031 shares of the health services provider’s stock valued at $284,000 after purchasing an additional 37 shares in the last quarter. IHT Wealth Management LLC raised its holdings in Cigna Group by 2.5% in the fourth quarter. IHT Wealth Management LLC now owns 1,535 shares of the health services provider’s stock worth $423,000 after purchasing an additional 38 shares during the period. Finally, Whetstone Capital Advisors LLC boosted its position in shares of Cigna Group by 4.9% during the fourth quarter. Whetstone Capital Advisors LLC now owns 829 shares of the health services provider’s stock worth $228,000 after purchasing an additional 39 shares in the last quarter. 86.99% of the stock is owned by institutional investors.

Cigna Group News Summary

Here are the key news stories impacting Cigna Group this week:

• Positive Sentiment: Cigna reported adjusted second-quarter earnings of $7.78 per share, above the roughly $7.60 consensus estimate, while revenue rose 7% year over year to approximately $71.7 billion. Cigna Healthcare revenue increased 9%, and Evernorth Health Services revenue grew 6%. Cigna Q2 results and outlook
• Positive Sentiment: Management raised its 2026 adjusted earnings outlook to at least $30.45 per share, implying approximately 10% earnings growth, supported by strength across the healthcare and pharmacy-benefit businesses. Cigna raises annual profit forecast
• Positive Sentiment: Analyst sentiment remains constructive: Barclays raised its price target from $304 to $310 while retaining an “equal weight” rating. A separate analysis highlighted CI’s discounted valuation, ongoing share repurchases, strong cash generation, and $1.56-per-share dividend. Cigna valuation analysis
• Neutral Sentiment: The earnings beat was accompanied by revenue that was slightly below some analyst estimates, and Barclays’ “equal weight” stance suggests the improved outlook may already be partly reflected in the stock.
• Negative Sentiment: Cigna expects lower growth in prescriptions for popular GLP-1 drugs. Because these treatments are a significant growth area for pharmacy services, slower utilization could temper future revenue and profit expansion. Cigna GLP-1 prescription outlook
• Negative Sentiment: Elevated medical costs and higher pharmacy expenses remain industrywide risks. Those pressures may explain why investors initially treated the guidance increase cautiously despite Cigna’s higher profit and broad-based operating growth.

Cigna Group Company Profile

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.